ClinicalTrials.gg
CompletedNCT02136524Updated Nov 2, 2016

A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule Formulation

A Phase 1 interventional study of cobimetinib and cobimetinib in Healthy Volunteer, sponsored by Genentech, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will be a Phase 1, open-label, randomized, 2-period, 2-treatment sequence crossover study to determine the relative bioavailability of cobimetinib administered as a single dose of the tablet formulation relative to a single dose of the capsule formulation to healthy male and female participants. A minimum of 24 participants (12 participants per sequence) will complete the study. Participants will be randomly assigned to 2 possible sequences (i.e., I: A/B, II: B/A) where the treatments are as follows: Treatment A: One cobimetinib tablet administered as a single oral dose after at least an 8-hour fast; Treatment B: Four cobimetinib capsules administered as a single oral dose after at least an 8-hour fast. The study is expected to last approximately 7 weeks.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female volunteers between 18 and 55 years of age, inclusive
  • between 18.5 to 32.0 kg/m2, inclusive;
  • Adequate renal, liver, and hematologic function
  • Participants who are in good health as determined by no findings from medical history, 12-lead , vital signs, and clinical laboratory evaluations

Exclusion criteria

Exclusion Criteria:

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder (as determined by the Investigator)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Capsule formulation

    Drug: cobimetinib

  • Experimental
    Tablet formulation

    Drug: cobimetinib

Interventions

  • Single, oral dose given as a tablet on Day 1 after a minimum 8 h fast

    Also known as: GDC-0973, XL-518

  • Single, oral dose given as 4 capsules on Day 1 after a minimum 8 h fast

    Also known as: GDC-0973, XL-518

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax)

    Time frame: Days 1 to 10 and 15 to 25 (1 to 10 of the second crossover sequence)

  2. Time to maximum concentration (tmax)

    Time frame: Days 1 to 10 and 15 to 25 (1 to 10 of the second crossover sequence)

  3. Area under the concentration-time curve (AUC)

    Time frame: Days 1 to 10 and 15 to 25 (1 to 10 of the second crossover sequence)

  4. Apparent terminal elimination rate constant

    Time frame: Days 1 to 10 and 15 to 25 (1 to 10 of the second crossover sequence)

  5. Half-life (t1/2)

    Time frame: Days 1 to 10 and 15 to 25 (1 to 10 of the second crossover sequence)

  6. Apparent clearance (CL/F)

    Time frame: Days 1 to 10 and 15 to 25 (1 to 10 of the second crossover sequence)

  7. Apparent volume of distribution (Vz/F)

    Time frame: Days 1 to 10 and 15 to 25 (1 to 10 of the second crossover sequence)

  8. Relative bioavailability (Frel)

    Time frame: Days 1 to 10 and 15 to 25 (1 to 10 of the second crossover sequence)

Secondary outcomes

  1. Incidence of adverse events

    Time frame: Up to 4 weeks

07

Study locations

1 site
  • Dallas, Texas 75247, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2014
First posted
May 13, 2014
Start
Apr 2014
Primary completionActual
May 2014
CompletionActual
May 2014
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02136524
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
May 13, 2014
Start date
Apr 2014
Primary completion
May 2014
Completion
May 2014
Last update
Nov 2, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cobimetinib

Start the discussion